Q1 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
[Interpreted] I'm Kashima, presenting the financial results for the first quarter fiscal year 2019 and the clinical development updates. Please look at Slide 3.
I would like to present the financial results for the first quarter based on IFRS core basis. Total revenue was JPY 117.5 billion, slightly up by JPY 1.6 billion year-on-year. Revenue grew in North America and China, but dropped in Japan.
Sales expenses declined mainly in North America, and R&D expenses decreased as well. As a result, core operating profit increased by JPY 3.9 billion year-on-year to JPY 22.3 billion.
Changes in fair value of contingent consideration was up by JPY 21 billion year-on-year, driven by favorable expenses due to the discontinuation of Phase III study of napabucasin for patients with pancreatic cancer. The operating profit as a result improved significantly from a year earlier to JPY 40.4 billion.
On the other hand, net profit attributable to owners of the parent fell sharply,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
